CERo Therapeutics Holdings, Inc. (NASDAQ:CERO) Short Interest Update

CERo Therapeutics Holdings, Inc. (NASDAQ:CERO) saw a significant growth in short interest during the month of November. As of November 15th, there was short interest totalling 7,860,000 shares, a growth of 391.3% from the October 31st total of 1,600,000 shares. Based on an average daily volume of 63,190,000 shares, the days-to-cover ratio is presently 0.1 days. Approximately 30.0% of the shares of the company are short sold.

CERo Therapeutics Stock Up 37.6 %

Shares of NASDAQ CERO traded up $0.06 during mid-day trading on Thursday, hitting $0.20. The company had a trading volume of 63,712,566 shares, compared to its average volume of 20,758,256. The business’s 50-day simple moving average is $0.12 and its 200-day simple moving average is $0.29. CERo Therapeutics has a 12 month low of $0.06 and a 12 month high of $12.80.

Insider Activity

In other news, major shareholder Bioventures Opportunities G. Yk sold 3,250,000 shares of the firm’s stock in a transaction dated Thursday, October 10th. The stock was sold at an average price of $0.10, for a total value of $325,000.00. Following the sale, the insider now directly owns 22,620,783 shares of the company’s stock, valued at approximately $2,262,078.30. This trade represents a 12.56 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, major shareholder Stuart M. Sloan sold 532,486 shares of the firm’s stock in a transaction dated Wednesday, September 25th. The shares were sold at an average price of $0.10, for a total value of $53,248.60. Following the completion of the sale, the insider now directly owns 21,067,956 shares in the company, valued at approximately $2,106,795.60. This represents a 2.47 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Corporate insiders own 18.00% of the company’s stock.

CERo Therapeutics Company Profile

CERo Therapeutics Holdings, Inc, an immunotherapy company, focuses on advancing the development of engineered T cell therapeutics for the treatment of cancer. Its lead program in hematologic malignancies targets an Eat Me signal upregulated on B cell and myeloid tumors. The company is based in South San Francisco, California.